Paris Brain Institute America’s Third Annual Dinner: A Transatlantic Bridge for Neuroscience

On October 14, 2025, in New York, the 3rd annual dinner of Paris Brain Institute America (PBIA), the U.S. sister organization of Paris Brain Institute, chaired by Martine Assouline, Co-Chair of the Institute’s Campaign Committee, took place. The event brought together the philanthropic and scientific community committed to fighting neurological and brain diseases.

The evening, attended by Professor Gérard Saillant, Honorary President of Paris Brain Institute, and Professor Stéphanie Debette, Executive Director, highlighted the progress and future perspectives of international research on neurodegenerative diseases.

A Strategic Partner for Paris Brain Institute

Created to support and expand Paris Brain Institute’s initiatives in the United States, PBIA mobilizes philanthropists, donors, and American scientific partners. Its mission is to strengthen transatlantic collaborations, accelerate innovation, and facilitate the translation of discoveries for the benefit of patients.

PBIA supports three major projects:

• Glioblastomas: targeting tumor adaptability and improving immunotherapy, in partnership with Harvard Medical School
• Severe traumatic brain injuries: developing a personalized approach for diagnosis and treatment, in partnership with Columbia University
• Alzheimer’s disease: improving understanding of the role of blood vessels

Additional collaborations with leading U.S. institutions are currently under development.

Outstanding Scientific Exchanges

During the dinner, presentations by Professor Stéphanie Debette, Professor Phil De Jager, and Professor Fanny Elahi highlighted the challenges of healthy brain aging and emphasized the importance of international collaboration in addressing neurodegenerative diseases.

A Collective Commitment to Research

Paris Brain Institute extends its sincere thanks to PBIA, its donors, and all American scientific partners. Their engagement directly contributes to advancing knowledge and developing new therapeutic solutions to better understand, prevent, and treat brain diseases, thereby enhancing the Institute’s international impact.